睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06439771,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:仅女性

    登记记录的入选字段

  2. Patients who are pathologically confirmed advanced/unresectable or metastatic breast cancer with HR-negative and HER2-negative,.

    入选标准第 3 条

  3. Patients with locally advanced or metastatic disease (according to the UICC and AJCC staging system [Version 8]) who are not candidates for curative surgery or radiotherapy.

    入选标准第 2 条

  4. Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC.

    入选标准第 5 条

    Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.

    入选标准第 8 条

    Have prior treatment with an agent targeting HER3.

    排除标准第 1 条

    Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.

    排除标准第 5 条

    Have any other primary malignancy within 5 years prior to the first dose of study drug.

    排除标准第 19 条

  5. Have at least 1 extracranial measurable lesion as a target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    入选标准第 6 条

  6. Patients with human immunodeficiency virus (HIV) infection.

    排除标准第 17 条

    Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

    排除标准第 18 条

  7. Lactating women, or women who are confirmed to be pregnant by pregnancy test within 3 days prior to the first dose.

    排除标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06439771,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Have been informed of the study before the start of the study and voluntarily sign name and date on the informed consent form.
  2. Patients with locally advanced or metastatic disease (according to the UICC and AJCC staging system [Version 8]) who are not candidates for curative surgery or radiotherapy.
  3. Patients who are pathologically confirmed advanced/unresectable or metastatic breast cancer with HR-negative and HER2-negative,.
  4. Patients who are confirmed HR positive and HER2-Zero-expression and HER2-Low-expression.
  5. Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC.
  6. Have at least 1 extracranial measurable lesion as a target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  7. Have Adequate organ and bone marrow function within 7 days prior to the first dose.
  8. Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
  9. Have a expected survival ≥ 3 months.
  10. Have ability and willingness to comply with protocol-specified visits and procedures.

排除标准:Exclusion Criteria:

  1. Have prior treatment with an agent targeting HER3.
  2. Have prior intolerance to treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor.
  3. Have been enrolled in another clinical study concurrently unless it is an observational clinical study or in the follow-up phase of an interventional study.
  4. Have insufficient washout period for prior anticancer therapy prior to first dose of the study drug.
  5. Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
  6. Have prior allogeneic bone marrow transplant or prior solid organ transplant.
  7. Have received treatment with systemic steroids.
  8. Have received any live vaccine within 4 weeks prior to the first dose of study drug or intend to receive a live vaccine during the study.
  9. Leptomeningeal metastases or carcinomatous meningitis, spinal cord compression.
  10. Brain metastases with the exceptions.
  11. Have uncontrolled or clinically significant cardiovascular and cerebrovascular disease.
  12. Have clinically significant concomitant pulmonary diseases.
  13. Have a diagnosis of Gilbert's syndrome.
  14. Have pleural effusion, abdominal effusion.
  15. Have a history of gastrointestinal perforation and or fistula within 6 months prior to the first dose.
  16. Have serious infection.
  17. Patients with human immunodeficiency virus (HIV) infection.
  18. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  19. Have any other primary malignancy within 5 years prior to the first dose of study drug.
  20. Have unresolved toxicities from prior anticancer therapy.
  21. Have a history of severe hypersensitivity reactions to the drug substance, inactive ingredients in the drug product, or other monoclonal antibodies.
  22. Lactating women, or women who are confirmed to be pregnant by pregnancy test within 3 days prior to the first dose.

引自 ClinicalTrials.gov, NCT06439771, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06439771,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06439771